Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
Syndax Pharmaceuticals announces FDA Priority Review for revumenib, a menin inhibitor for relapsed/refractory KMT2Ar acute leukemia, with a PDUFA target action date of September 26, 2024, under the FDA's Real-Time Oncology Review Program.
Reference News
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
Syndax Pharmaceuticals announces FDA Priority Review for revumenib, a menin inhibitor for relapsed/refractory KMT2Ar acute leukemia, with a PDUFA target action date of September 26, 2024, under the FDA's Real-Time Oncology Review Program.